Provention Bio Announces China Deal For Autoimmune Program

  • Provention Bio Inc (NASDAQ: PRVB) is making its way into China with a new deal with a subsidiary of Huadong Medicine to work on PRV-3279, a bispecific antibody-based molecule targeting CD32B and CD79B, in China, Hong Kong, Macau, and Taiwan. Provention will retain all rights to PRV-3279 in the rest of the world.
  • Provention will get $6 million upfront and up to $11.5 million in funding over the next three years to cover expected research costs. It will also receive regulatory and commercial milestones of up to $172 million. It is also eligible to receive low-to-mid double-digit royalties as a percentage of net sales of PRV-3279 by Huadong in Greater China.
  • The company plans to begin a Phase 2a trial of PRV-3279 in systemic lupus erythematosus in the second half of 2021 and expects a portion of such trial to be conducted in China.
  • PRV-3279 is a humanized diabody (a bispecific DART molecule) targeting the B cell surface proteins, CD32B and CD79B. Simultaneous engagement of the CD32B and CD79B receptors triggers B cell function inhibition and suppression of autoantibody production, thereby regulating B cells without causing depletion.
  • Price Action: PRVB stock is down marginally by 0.14% at $14.49 in market trading hours on last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechM&ANewsHealth CareSmall CapFDAGeneralautoimmune diseasesChina
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!